Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization

A molecular test with proven clinical success

Benjamin R. Kipp, Emily G Barr Fritcher, Jennifer E. Pettengill, Kevin C. Halling, Amy C. Clayton

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors.

Original languageEnglish (US)
Pages (from-to)610-619
Number of pages10
JournalCancer cytopathology
Volume121
Issue number11
DOIs
StatePublished - 2013

Fingerprint

Fluorescence In Situ Hybridization
Cell Biology
Neoplasms
Aneuploidy
Sclerosing Cholangitis
Aptitude
Cholangiocarcinoma
Clinical Laboratory Techniques
Health Care Costs
Pathologic Constriction
Adenocarcinoma
Genome

Keywords

  • Bile duct
  • Cholangiocarcinoma
  • Fluorescence in situ hybridization
  • Pancreas
  • Primary sclerosing cholangitis
  • UroVysion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization : A molecular test with proven clinical success. / Kipp, Benjamin R.; Fritcher, Emily G Barr; Pettengill, Jennifer E.; Halling, Kevin C.; Clayton, Amy C.

In: Cancer cytopathology, Vol. 121, No. 11, 2013, p. 610-619.

Research output: Contribution to journalArticle

Kipp, Benjamin R. ; Fritcher, Emily G Barr ; Pettengill, Jennifer E. ; Halling, Kevin C. ; Clayton, Amy C. / Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization : A molecular test with proven clinical success. In: Cancer cytopathology. 2013 ; Vol. 121, No. 11. pp. 610-619.
@article{a5441fe9ba1349cb8668e914ba5c6021,
title = "Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: A molecular test with proven clinical success",
abstract = "The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors.",
keywords = "Bile duct, Cholangiocarcinoma, Fluorescence in situ hybridization, Pancreas, Primary sclerosing cholangitis, UroVysion",
author = "Kipp, {Benjamin R.} and Fritcher, {Emily G Barr} and Pettengill, {Jennifer E.} and Halling, {Kevin C.} and Clayton, {Amy C.}",
year = "2013",
doi = "10.1002/cncy.21303",
language = "English (US)",
volume = "121",
pages = "610--619",
journal = "Cancer cytopathology",
issn = "1934-662X",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization

T2 - A molecular test with proven clinical success

AU - Kipp, Benjamin R.

AU - Fritcher, Emily G Barr

AU - Pettengill, Jennifer E.

AU - Halling, Kevin C.

AU - Clayton, Amy C.

PY - 2013

Y1 - 2013

N2 - The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors.

AB - The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors.

KW - Bile duct

KW - Cholangiocarcinoma

KW - Fluorescence in situ hybridization

KW - Pancreas

KW - Primary sclerosing cholangitis

KW - UroVysion

UR - http://www.scopus.com/inward/record.url?scp=84894672553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894672553&partnerID=8YFLogxK

U2 - 10.1002/cncy.21303

DO - 10.1002/cncy.21303

M3 - Article

VL - 121

SP - 610

EP - 619

JO - Cancer cytopathology

JF - Cancer cytopathology

SN - 1934-662X

IS - 11

ER -